PureIMS participating in Biotech Showcase™ 2022

PureIMS aims to find a partner for its lead program Levodopa Cyclops™

Roden — December 22, 2021PureIMS today announced that it is participating in Biotech Showcase™ 2022.

PureIMS is a clinical stage pharmaceutical and medication systems company developing a portfolio of products addressing acute and unmet medical needs. These products are based on the company’s proprietary, preloaded and disposable dry powder inhaler (DPI) Cyclops™. Cyclops™ can be manufactured in a cost-effective way. Its design and functionality are patent protected until 2035. One Cyclops™ application is already on the market under a named patient program.

The company aims to obtain marketing authorization for its lead program Levodopa Cyclops™ and is interested in discussions with Pharma companies who, under a license-based partnership agreement, would strengthen these development activities and become responsible for future commercialization. An important basis for prioritizing Levodopa Cyclops™ is its potential to achieve initial marketing authorization through accelerated or abbreviated regulatory routes, i.e. within approximately 3 years.  PureIMS also supports pharma/biotech partners, applying the Cyclops™-based inhalation route for their drug of choice.

About Biotech Showcase™

Biotech Showcase™ is devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and (bio)pharmaceutical executives in one place. Investors and (bio)pharmaceutical executives from around the world gather in San Francisco during this week which sets the tone for the coming year. Now in its 14th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase™ is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry. Given the ongoing developments with the COVID-19 pandemic, like the previous edition, Biotech Showcase will be a fully virtual event.

About PureIMS

PureIMS is a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops™. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global Pharma companies, and with successful service providers.

PureIMS’ lead candidate, Levodopa Cyclops™, is in the final development stage as rescue therapy for OFF-episodes in Parkinson’s disease. One product, Colistin Cyclops™, is already marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. Some three other clinical programs – including Epinephrine Cyclops™ for impending (food) allergy induced anaphylaxis – are being explored in an early clinical stage.

PureIMS also supports pharma/biotech partners, applying the Cyclops™-based inhalation route for their drug of choice.

PureIMS has developed a proprietary dry powder inhaler (DPI) called Cyclops™. Cyclops™ is an easy-to-handle, pre-loaded, credit card sized and disposable DPI, developed for high dose inhalation powders and is particularly suitable in situations requiring acute intervention. It can be produced in a cost-effective way because of its simple yet sophisticated proprietary design. Upon inhalation it uses the patient’s breath to disperse the dry powder formulation into small particles appropriately sized for deep lung deposition. Cyclops™ has several advantages over standard-of-care DPIs across key therapeutic areas. These attributes enable its hygienic and effective use on a worldwide scale.

For more information, press, investors and pharma only:

Jeroen Tonnaer, CBDO

+31(0)50 205 3325